Epigenica Secures $2.2 Million to Propel Innovative Solutions
Epigenica Closes $2.2 Million Investment Round to Scale Cutting-Edge Epigenetic Solutions
Financing to accelerate commercialization of flagship products, service business, and entrance into U.S. market
In a significant step towards advancing its pioneering epigenetic solutions, Epigenica AB has closed a $2.2 million investment round aimed at fostering growth and entering key markets. This funding round attracted the support of notable investors including Voima Ventures, Navigare Ventures, Leksell Social Ventures, and Almi Invest.
As biological research evolves, the integration of powerful new tools has allowed for enhanced data generation from RNA, proteins, and metabolites. These developments have been pivotal, giving rise to multi-omics approaches that adopt a more holistic view of biological systems. In this intricate landscape, epigenetics emerges as a crucial factor, shedding light on how biological processes are organized and regulated. Epigenica’s proprietary EpiFinder platform stands out by enabling the simultaneous analysis of diverse epigenetic markers across numerous samples while maintaining high resolution and efficiency.
Stina Wallmark, Investment Director at Voima Ventures, expressed enthusiasm regarding the potential of epigenetics, particularly its implications in sectors such as oncology, longevity, and drug development. She stated, "Epigenica enables fast, scalable, and affordable analysis of epigenetic biomarkers, thereby empowering researchers to tap into the full potential of multi-omics in the quest for innovative diagnostics and therapies."
Epigenica’s CEO, Mohamad Takwa, remarked on the technological advancements made since the company’s inception. He said, "We have refined our technology into an extensive range of products catering to diverse epigenetic applications. We envision various significant product launches within the year, which will empower our clients to enhance and broaden their research endeavors. I am excited to welcome Voima Ventures, Navigare Ventures, and Leksell Social Ventures and deeply appreciate the continual support and trust of our existing shareholders. This funding strongly endorses our scientific and commercial growth."
The funds raised will expedite the development and commercialization of Epigenica’s flagship offerings, such as the already available EpiFinder Genome and the impending EpiFinder Global and EpiFinder cNUC kits. Additionally, it will bolster the expansion of the company's service offerings and data infrastructure, paving the way for an entrance into the U.S. market.
About Epigenica
Epigenica is a prominent life sciences technology company that is revolutionizing high-throughput epigenetic solutions specifically tailored for research, diagnostics, and drug development. Utilizing the proprietary EpiFinder platform, Epigenica enables simultaneous analyses of various epigenetic markers across a multitude of samples with exceptional resolution and efficiency at an economical rate. The company boasts an extensive product portfolio designed to accommodate different applications across oncology, pharmaceutical development, and longevity.
Empowered by Epigenica's patented high-throughput, multiplex, quantitative ChIP-seq technology (hmqChIP), the platform provides scalable and cost-effective epigenomic profiling across assorted starting materials. Epigenica is dedicated to assisting customers in producing actionable insights that advance multi-omics and translational research, facilitate biomarker discovery, and accelerate next-generation sequencing applications aimed at enhancing human health.
Corporate Information
Mohamad Takwa, Ph.D., serves as the CEO of Epigenica. The company maintains a strong commitment to advancing science and innovation in the epigenetics space.
Frequently Asked Questions
What is the purpose of the $2.2 million investment?
The investment aims to accelerate the commercialization of Epigenica's flagship products, enhance their service offerings, and support their entry into the U.S. market.
Who are the key investors in this funding round?
Key investors include Voima Ventures, Navigare Ventures, Leksell Social Ventures, and Almi Invest.
What unique technology does Epigenica utilize?
Epigenica utilizes the EpiFinder platform for simultaneous analysis of multiple epigenetic markers across many samples, offering high resolution and efficiency.
How does epigenetics impact biological research?
Epigenetics plays a vital role in understanding how lifestyle and environmental factors influence gene expression, which has implications in areas such as oncology and drug development.
What future product launches are expected from Epigenica?
Epigenica anticipates launching new products, including the EpiFinder Global and EpiFinder cNUC kits, in the near future.
About The Author
Contact Henry Turner privately here. Or send an email with ATTN: Henry Turner as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
